https://bavdegalutamideinhibit....or.com/off-label-int
Recently, chronic kidney disease has gained an additional treatment option: the sodium-glucose cotransporter 2 inhibitor, dapagliflozin. The potential for pairing sparsentan with dapagliflozin is worthy of exploration. This crossover study, employing a single sequence and an open-label design, sought to identify if interactions between sparsentan and dapagliflozin impacted the pharmacokinetics (PK) of dapagliflozin. The inactive metabol
Like
Comment
Share
